Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ceregene Receives Additional Grant From Michael J Fox Foundation
Ceregene has announced that the Michael J Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company’s Phase 2 trial of CERE-120
Ceregene has announced that the Michael J Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company’s Phase 2 trial of CERE-120
Daiichi Sankyo and Eli Lilly have announced that Effient (prasugrel), a new antiplatelet medicine, is now available in pharmacies across the US. The FDA approved Effient tablets is
US-based Merck and Schering-Plough, and their cholesterol JV, Merck/Schering-Plough Pharmaceuticals (MSP) have signed an agreement to resolve the civil class action litigation for $41.5 million. The lawsuit, currently
Labopharm has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada, for its novel formulation of the antidepressant – trazodone. The company’s NDS
Addrenex has formed a partnership with Dream Pharma to advance the treatment of adrenergic-related conditions worldwide. Addrenex has licensed the right to manufacture, market and sell its lead
Novogen and Marshall Edwards (MSHL) have signed a license agreement for MSHL to develop and commercialize the oncology compound, NV-128. The terms of the license consist of –
Baxter has completed production of its first commercial batches of celvapan A/H1N1 pandemic vaccine, and is discussing plans for distribution with national health authorities. Baxter plans to deliver
NeurogesX has announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) date from August 16, 2009 to November 16, 2009 to review the new
Genzyme has received approval from the European Commission for the marketing authorization of Mozobil (plerixafor injection). It is likely to provide a new option for patients with blood
GeoVax has provided updates on its ongoing and planned human clinical trials – Phase 2a Preventive and Phase 1 Therapeutic (in the planning stage). The Preventative trial, designated